Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia

References

• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Wang HS, Qian XW, et al. Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia. Ann Transl Med. 2019;7:296.
   PubMed Web of Science ®Google Scholar
• Demir S, Boldrin E, Sun Q, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:170–181.
   PubMed Web of Science ®Google Scholar
• Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41–55.
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers . 2011;3:994–1013.
   PubMedGoogle Scholar
• Mantovani F, Collavin L, Sal D. G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199–212.
   PubMed Web of Science ®Google Scholar
• Hernandez Borrero LJ, El-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–2165.
   PubMed Web of Science ®Google Scholar
• Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185–3193.
   PubMed Web of Science ®Google Scholar
• Irving JA, Enshaei A, Parker CA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128:911–922.
   PubMed Web of Science ®Google Scholar
• Weng W, Zhang P, Ruan J, et al. Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia. Oncol Lett. 2020;19:549–556.
   PubMed Web of Science ®Google Scholar
• Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–252.
   PubMed Web of Science ®Google Scholar
• Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin Cancer Biol. 2020;84:144–152.
   PubMed Web of Science ®Google Scholar
• Flach J, Shumilov E, Wiedemann G, et al. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. Hematol Oncol. 2020;38:425–431.
   PubMed Web of Science ®Google Scholar
• Ishida H, Iguchi A, Aoe M, et al. Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing. Ann Hematol. 2019;98:657–668.
   PubMed Web of Science ®Google Scholar
• Kohlmann A, Klein HU, Weissmann S, et al. The ınterlaboratory RObustness of next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25:1840–1848.
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies – the next generation. Nat Rev Genet. 2010;11:31–46.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405–424.
   PubMed Web of Science ®Google Scholar
• Fortuno C, Lee K, Olivier M, et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat. 2021;42:223–236.
   PubMed Web of Science ®Google Scholar
• Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865–876.
   PubMed Web of Science ®Google Scholar
• Landrum MJ, Chitipiralla S, Brown GR, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48: D835–D844.
   PubMed Web of Science ®Google Scholar
• Pui CH. Precision medicine in acute lymphoblastic leukemia. Front Med. 2020;14:689–700.
   PubMed Web of Science ®Google Scholar
• Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the children’s oncology group. Blood. 2011;118:3080–3087.
   PubMed Web of Science ®Google Scholar
• Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.
   PubMed Web of Science ®Google Scholar
• Qian M, Cao X, Devidas M, et al. TP53 germline variations ınfluence the predisposition and prognosis of B-Cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36:591–599.
   PubMed Web of Science ®Google Scholar
• Stengel A, Schnittger S, Weissmann S, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124:251–258.
   PubMed Web of Science ®Google Scholar
• Stengel A, Kern W, Haferlach T, et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705–711.
   PubMed Web of Science ®Google Scholar
• Richter-Pechanska P, Kunz JB, Hof J, et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 2017;7:e523.
   PubMed Web of Science ®Google Scholar
• Harutyunyan A, Klampfl T, Cazzola M, et al. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488–490.
   PubMed Web of Science ®Google Scholar
• Jethwa A, Hullein J, Stolz T, et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol. 2013;163:496–500.
   PubMed Web of Science ®Google Scholar
• Chang MT, Asthana S, Gao SP, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155–163.
   PubMed Web of Science ®Google Scholar
• Kurniawan AN, Hongyo T, Hardjolukito ES, et al. Gene mutation analysis of sinonasal lymphomas in Indonesia. Oncol Rep. 2006;15:1257–1263.
   PubMed Web of Science ®Google Scholar
• Natan E, Baloglu C, Pagel K, et al. Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol. 2011;409(3):358–368.
   PubMed Web of Science ®Google Scholar
• Murnyak B, Hortobagyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7:64910–64920.
   PubMedGoogle Scholar
• Cole AJ, Dwight T, Gill AJ, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;6:26191.
   PubMed Web of Science ®Google Scholar
• Yu CH, Chang WT, Jou ST, et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci. 2020;111:229–238.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Eveillard M, Lok A, et al. p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell. Blood Rev. 2017;31:251–259.
   PubMed Web of Science ®Google Scholar
• Ye F, Wang T, Liu A, et al. Clinical significance of TP53 abnormalities in newly diagnosed multiple myeloma. Turk J Haematol. 2021;38:246–253.
   PubMed Web of Science ®Google Scholar
• Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4:5165–5173.
   PubMed Web of Science ®Google Scholar
• Prochazka KT, Pregartner G, Rucker FG, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104:516–523.
   PubMed Web of Science ®Google Scholar
• Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29:877–885.
   PubMed Web of Science ®Google Scholar
• Zerdoumi Y, Lanos R, Raad S, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26:2812.
   PubMed Web of Science ®Google Scholar
• Wong RP, Tsang WP, Chau PY, et al. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther. 2007;6:1054-1061.
   Google Scholar
• Uddin MB, Roy KR, Hosain SB, et al. An N(6)-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem Pharmacol. 2019;160:134–145.
   PubMed Web of Science ®Google Scholar
• Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847–860.
   PubMed Web of Science ®Google Scholar